ECO 2026
ECO 2026 12 - 15 May 2026

Gastrointestinal Tolerability of Once-Daily Oral Semaglutide 25 mg in Adults with Overweight or Obesity, and the Relationship with Weight Loss: A Post Hoc Analysis of the OASIS 4 Trial

Authors :

Domenica Rubino1;  Oscar Birkhan2; Agnieszka Klimek-Abercrombie2; Chaithra Shaji3 ; Minh Chau Tran2;  Sean Wharton4 
Affiliations
View Details Hide Details
Download .PDF
{{ getPageNum(PDFPage) }}
Keywords
Obesity
Congress poster
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)